[Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
After brief considerations about clinical course and diagnosis in multiple sclerosis, the members of the BCTRIMS present some recommendations for the use of the immunomodulatory drugs in the treatment of this disease.
Tilbery
C P
CP
Moreira
M A
MA
Mendes
M F
MF
Lana-Peixoto
M A
MA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000068717:Glatiramer Acetate; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use; D012720:Severity of Illness Index
D000276:Adjuvants, Immunologic; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a